Opening Up Innovation
The pmlive website noted that the [pharma] industry is increasingly open to academic collaborations and alongside this a more radical step can be seen in pharma’s willingness to move beyond ‘not invented here’ and take part in ‘open innovation’ initiatives. The trend is an acknowledgement that it is impossible to maintain a sustainable R&D pipeline from internal efforts alone. For GlaxoSmithKline its pharma open innovation efforts began with diseases of the developing world, such as malaria – where it offered researchers free access to a ‘virtual library’ of tens of thousands of compounds that had been laying idle. The company’s open innovation model was subsequently adapted so that it could be applied to different areas.
Click here to read the full article.
